Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 228
- Registration Number
- NCT03250910
- Locations
- 🇨🇳
National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Registration Number
- NCT03105349
- Locations
- 🇪🇸
Hospital Infanta Leonor, Madrid, Spain
🇪🇸Hospital Univ. Gregorio Marañon, Madrid, Spain
🇪🇸Hospital Univ. La Paz, Madrid, Spain
Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Sheikh Zayed Medical College
- Target Recruit Count
- 98
- Registration Number
- NCT03090035
- Locations
- 🇵🇰
Muhammad Zafar Majeed Babar, Sadiqabad, Punjab, Pakistan
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 141
- Registration Number
- NCT03020082
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03020095
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2019-01-09
- Target Recruit Count
- 70
- Registration Number
- NCT03004625
- Locations
- 🇨🇳
Kaohsiung Medical Universsity, Kaohsiung, Taiwan
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT02996682
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT02994056
- Locations
- 🇺🇸
Northwestern Memorial Hospital; Clinical Research Unit, Chicago, Illinois, United States
🇺🇸Tampa General Medical Group, Tampa, Florida, United States
🇺🇸Digestive Disease Associates, PA, Catonsville, Maryland, United States
Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 10000
- Registration Number
- NCT02992457
- Locations
- 🇪🇬
Tanta university hospital, Tanta, Egypt
🇪🇬Sherief Abd-Elsalam, Tanta, Egypt
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- National Liver Institute, Egypt
- Target Recruit Count
- 41
- Registration Number
- NCT02985281
- Locations
- 🇪🇬
National liver institute, Segin el Kom, Menofia, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.